The Concept
Fecal microbiota transplantation (FMT) involves transferring processed stool from a healthy, screened donor into the gastrointestinal tract of a patient with a disrupted microbiome. The principle is simple: replace a damaged ecosystem with an intact one. The practice is ancient — documented in 4th-century Chinese medicine as "yellow soup" — but its modern clinical validation began with the treatment of recurrent Clostridioides difficile infection (CDI).
The C. difficile Success Story
C. difficile thrives when antibiotic exposure decimates the normal colonic flora, eliminating competitive exclusion. Standard antibiotic treatment (vancomycin, fidaxomicin) kills C. difficile but does not restore the protective community, leading to recurrence rates of 20 to 30 percent after a first episode and over 60 percent after multiple episodes. FMT restores microbial diversity and competitive exclusion in a single procedure, achieving cure rates of 80 to 90 percent for recurrent CDI. This is among the most dramatic treatment effects in modern medicine.
FDA-Approved Products
In 2022 and 2023, the FDA approved two microbiota-based therapeutics: REBYOTA (fecal microbiota, live — administered rectally) and VOWST (fecal microbiota spores, live — oral capsules). Both are approved specifically for preventing CDI recurrence in adults who have completed antibiotic treatment. Their approval represents a landmark in microbiome therapeutics, transitioning FMT from an unregulated procedure to a standardised pharmaceutical product.
Beyond C. difficile: Mixed Results
Enthusiasm for FMT in other conditions — IBD, IBS, metabolic syndrome, obesity, autism — has outpaced evidence. In ulcerative colitis, multiple RCTs have shown that FMT can induce clinical remission in a subset of patients, but response rates vary widely (20 to 40 percent), optimal donor selection criteria remain unclear, and sustained engraftment is inconsistent. For Crohn's disease, IBS, and metabolic conditions, evidence is preliminary and largely limited to small, heterogeneous trials.
Safety Considerations
FMT carries risks that must be weighed against benefits: transmission of infection (including multidrug-resistant organisms, viral infections including SARS-CoV-2, and parasites) has been documented when donor screening is inadequate. In 2019, the FDA issued a safety alert after a patient death from extended-spectrum beta-lactamase (ESBL)-producing E. coli transmitted via FMT. Rigorous donor screening protocols — including stool and blood testing for pathogens, assessment of medical history, and quarantine periods — are essential.
The Future: Defined Consortia
Rather than transplanting entire stool (with its undefined composition), research is moving toward defined microbial consortia — carefully selected mixtures of cultured bacterial strains. VE303, a defined consortium of 8 Clostridia strains, showed efficacy in preventing CDI recurrence in a Phase 2 trial. These "designer" products offer manufacturing consistency, eliminable pathogen risk, and the potential for condition-specific tailoring — though they sacrifice the ecological complexity of complete FMT.